CEPI to develop 'variant-proof' vaccine, partners Bharat Biotech

"Our expertise in product development and innovation, especially with novel adjuvants and platform technologies will add to the strong partnership with CEPI, ExcellGene, and the University of Sydney," Krishna Ella, MD of Bharat Biotech, said in a statement.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/SKtpX5m
via IFTTT